SEC Form SC 13G filed by Immuneering Corporation

1/26/24 4:23:44 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMRX alert in real time by email

SC 13G 1 us45254e1073_012624.txt us45254e1073_012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Immuneering Corp -------------------------------------------------------- (Name of Issuer) Class A Common Stock -------------------------------------------------------- (Title of Class of Securities) 45254E107 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45254E107 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2086738 (6) Shared voting power 0 (7) Sole dispositive power 2097406 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2097406 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 7.2% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Immuneering Corp Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Class A Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2097406 Percent of class 7.2% Number of shares as to which such person has: Sole power to vote or to direct the vote 2086738 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2097406 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Immuneering Corp. No one person's interest in the common stock of Immuneering Corp is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 26, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Advisors, LLC BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary

Get the next $IMRX alert in real time by email

Recent Analyst Ratings for

$IMRX

Date	Price Target	Rating	Analyst
10/31/2025	$15.00	Outperform	Leerink Partners
12/13/2024		Equal-Weight → Underweight	Morgan Stanley
3/15/2024	$20.00 → $15.00	Buy	Needham
3/15/2024		Outperform → Market Perform	TD Cowen
3/15/2024	$16.00 → $3.00	Buy → Hold	Jefferies
12/1/2023	$20.00	Buy	Needham
6/26/2023	$25.00	Outperform	Oppenheimer
4/19/2023	$5.00 → $14.00	Underweight → Equal-Weight	Morgan Stanley

More analyst ratings

SEC Form SC 13G filed by Immuneering Corporation

1/26/24 4:23:44 PM ET

$IMRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMRX alert in real time by email

Recent Analyst Ratings for

$IMRX

Date	Price Target	Rating	Analyst
10/31/2025	$15.00	Outperform	Leerink Partners
12/13/2024		Equal-Weight → Underweight	Morgan Stanley
3/15/2024	$20.00 → $15.00	Buy	Needham
3/15/2024		Outperform → Market Perform	TD Cowen
3/15/2024	$16.00 → $3.00	Buy → Hold	Jefferies
12/1/2023	$20.00	Buy	Needham
6/26/2023	$25.00	Outperform	Oppenheimer
4/19/2023	$5.00 → $14.00	Underweight → Equal-Weight	Morgan Stanley

More analyst ratings

SEC Form SC 13G filed by Immuneering Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IMRX

SEC Form SC 13G filed by Immuneering Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IMRX

$IMRX
Analyst Ratings

Leerink Partners initiated coverage on Immuneering with a new price target

Immuneering Corporation downgraded by Morgan Stanley

Needham reiterated coverage on Immuneering Corporation with a new price target

$IMRX
SEC Filings

Immuneering Corporation filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Immuneering Corporation

Immuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IMRX
Leadership Updates

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

$IMRX
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

$IMRX
Insider Trading

SEC Form 4 filed by Director Keating Laurie

SEC Form 4 filed by Director Feinberg Peter

Director Feinberg Peter bought $50,025 worth of shares (7,500 units at $6.67), increasing direct ownership by 5% to 156,766 units (SEC Form 4)

$IMRX
Press Releases

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

$IMRX
Insider Purchases

Director Feinberg Peter bought $50,025 worth of shares (7,500 units at $6.67), increasing direct ownership by 5% to 156,766 units (SEC Form 4)

Chief Accounting Officer Morales Mallory bought $1,917 worth of shares (300 units at $6.39), increasing direct ownership by 1% to 27,533 units (SEC Form 4)

CHIEF PEOPLE OFFICER Neufeld Leah R bought $5,103 worth of shares (800 units at $6.38), increasing direct ownership by 4% to 23,344 units (SEC Form 4)

$IMRX
Financials

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

SEC Form SC 13G filed by Immuneering Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $IMRX

SEC Form SC 13G filed by Immuneering Corporation

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $IMRX

$IMRX Analyst Ratings

Leerink Partners initiated coverage on Immuneering with a new price target

Immuneering Corporation downgraded by Morgan Stanley

Needham reiterated coverage on Immuneering Corporation with a new price target

$IMRX SEC Filings

Immuneering Corporation filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Immuneering Corporation

Immuneering Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IMRX Leadership Updates

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

$IMRX Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

$IMRX Insider Trading

SEC Form 4 filed by Director Keating Laurie

SEC Form 4 filed by Director Feinberg Peter

Director Feinberg Peter bought $50,025 worth of shares (7,500 units at $6.67), increasing direct ownership by 5% to 156,766 units (SEC Form 4)

$IMRX Press Releases

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

$IMRX Insider Purchases

Director Feinberg Peter bought $50,025 worth of shares (7,500 units at $6.67), increasing direct ownership by 5% to 156,766 units (SEC Form 4)

Chief Accounting Officer Morales Mallory bought $1,917 worth of shares (300 units at $6.39), increasing direct ownership by 1% to 27,533 units (SEC Form 4)

CHIEF PEOPLE OFFICER Neufeld Leah R bought $5,103 worth of shares (800 units at $6.38), increasing direct ownership by 4% to 23,344 units (SEC Form 4)

$IMRX Financials

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Recent Analyst Ratings for
$IMRX

Recent Analyst Ratings for
$IMRX

$IMRX
Analyst Ratings

$IMRX
SEC Filings

$IMRX
Leadership Updates

$IMRX
Large Ownership Changes

$IMRX
Insider Trading

$IMRX
Press Releases

$IMRX
Insider Purchases

$IMRX
Financials